Abstract: OBJECTIVE To evaluate the efficacy and safety of intravitreal injection of ranibizumab combined with triamcinolone acetonide(IVR+IVT) versus ranibizumab(IVR) in the treatment of macular edema secondary to retinal vein occlusion(RVO). METHODS PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang database were searched from building the library to January 2019 for randomized controlled trials on the treatment of RVO with IVR+IVT versus IVR. Then, the Cochrane RCTs score scale was used to evaluate the relevant data and the quality of the research literature, and the Cochrane Collaboration's software RevMan 5.3 was used to analyze. RESULTS Four RCTs were included with 215 cases and 217 eyes. Meta-analysis results indicated that the center macular thickness(CMT) in IVR+IVT patients in 3 month follow-up showed better than that in IVR patients, which was no statistical difference between 2 groups in 1, 2, 4, 5, 6 months. The best corrected visual acuity(BCVA) was improved in 4 studies compared with before treatment. In 2 cases, there were significant differences in 1 month, but no significant difference was found in 2, 3, 4, 5 and 6 months. In terms of the incidence of adverse reactions, IVR+IVT group's intraocular hypertension was significantly higher than that in the IVR group, but there was no significant difference in the occurrence of cortical cataract between the 2 groups. IVR+IVT group was significantly less than the IVR group in the number of injections, and the difference was statistically significant. CONCLUSION IVR+IVT and IVR are effective in the treatment of RVO, but there is a difference in the reduction of CMT in 3 month follow-up and the improvement of BCVA in 1 month follow-up. Although IVR+IVT may increase the adverse reaction of intraocular pressure elevation, it can also reduce the injection times and the burden of patients. Clinicians can select appropriate treatment methods according to the actual situation.